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Summary 
Expression of CD45, the major transmembrane protein tyrosine phosphatase expressed on lymphoid 
cells, is required for optimal T cell receptor (TCR) signal transduction. We and others recently 
have demonstrated that surface expression of the cytoplasmic domain of CD45 in the absence 
of its extracdlular and transmembrane domains is sufficient to restore TCR-mediated signaling 
events in CD45-deficient cell lines. Here we demonstrate that a single domain nonreceptor tyrosine 
phosphatase from yeast expressed as a chimeric protein with the extracellular and transmembrane 
domains of a major histocompatibility complex dass I molecule also is able to restore proximal 
and distal TCR-mediated signal transduction events in the CD45-deficient T  cell line J45.01. 
Ligation of the TCR on the cell line expressing the yeast phosphatase chimera results in the 
induction of protein tyrosine kinase activity, soluble inositol phosphate generation, and expression 
of the CD69 activation antigen. Furthermore, a phosphatase-inactive version of this molecule 
is unable to restore signal transduction, providing the first formal evidence that plasma membrane 
associated tyrosine phosphatase activity is required for TCR-mediated signaling. 
number of studies from several laboratories have demon- 
strated that surface  expression of the CD45 tyrosine phos- 
phatase is critical for optimal signal transduction initiated by 
ligation of the T cell antigen receptor (TCR) (1-5).  Studies 
from our laboratory and others have shown that the TCR 
is uncoupled from its signaling pathways in CD45-deficient 
cell lines (2-5).  Transfection  of wild-type CD45 (2, 5, 6), 
or chimeric molecules containing the cytoplasmic domain of 
CD45 (7-9), restores signaling ability to several CD45-defi- 
cient cell lines. 
One model for the role of CD45 in the regulation of TCR- 
mediated signal transduction suggests that this molecule func- 
tions to control the state of phosphorylation of the negative 
regulatory COOH-terminal tyrosine residue present in the 
lck and/or  fyn protein tyrosine kinases  (PTK) 1.  A  large 
number of studies have shown that ligation of the TCR in- 
duces a series of biochemical signaling events, the earliest of 
which is the activation of a PTK (10, 11). As the TCR does 
not possess intrinsic kinase activity, one or more cellular PTK 
must be recruited. Candidates for the TCR-activated PTK 
include two members of the src family, lck and fyn, and a 
syk family kinase, ZAP-70. Increasing evidence suggests that 
members of both PTK families are important in T cell acti- 
vation (12-16). Furthermore, recent studies suggest that ac- 
1 Abbrevidtions  used  in  this  paper: IP,  inositol  phosphates;  PLC'gl, 
phospholipase C~/1; IrI'K, protein tyrosine kinase. 
tivation of members of the PTK families is sequential, with 
activation of lck and/or fyn preceding ZAP-70 recruitment 
(17). As hyperphosphorylation of src family PTK on their 
COOH-terminal tyrosine results in decreased enzymatic ac- 
tivity (18, 19), the model predicts that in the absence of CD45 
the most proximal signaling events associated with TCR li- 
gation would be impaired. 
We have found this to be the case in J45.01, a CD45-deficient 
variant of the Jurkat human T  cell leukemic line. Stimula- 
tion of the TCR on this cell fails to result in the induction 
of PTK activity (3); and as predicted, also fails to result in 
the appearance of second messengers downstream of the PTK, 
including soluble inositol phosphates (IP), and increased levels 
of intracellular flee calcium (3). Transfection  of full-length 
CD45 cDNA corrects the signaling defect (6). Additionally, 
we and others recently have demonstrated that surface ex- 
pression of the cytoplasmic domain of CD45, in the absence 
of its extracellular and transmembrane domains, also rescues 
proximal (7-9) and distal (20) TCR-initiated signaling events, 
although not to wild-type levels, thus suggesting that the 
cytoplasmic domain of CD45 is necessary and sufficient for 
TCR-mediated signal transduction. 
There is considerable  evidence to support the model for 
the role of CD45 described above. CD45 has been shown 
to dephosphorylate  lck in vitro (21). Additionally, in a number 
of CD45-deficient cells, src family kinases have been shown 
to be hyperphosphorylated on their COOH-terminal tyro- 
sine residues (5, 21-23). Finally, coimmunoprecipitation  studies 
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sociates with lck in a number of human T cell lines (24-27). 
Similar  to essentially all transmembrane  tyrosine phospha- 
tases, the cytoplasmic domain of CD45 contains two tandem 
catalytic domains that are responsible for the enzymatic ac- 
tivity of the molecule (28).  There are to date, however, no 
studies formally demonstrating that it is the enzymatic ac- 
tivity of CD45 that is essential for its function to regulate 
signaling  via the TCK.  Similarly,  there are as yet no data 
addressing whether there are features of CD45 independent 
of its enzymatic activity which are required for the support 
of TCK function. 
In an effort to investigate these questions more thoroughly, 
we transfectedJ45.01 with a eDNA encoding a chimeric trans- 
membrane protein consisting of a single domain nonreceptor 
tyrosine phosphatase from yeast (29) coupled to the extracd- 
lular and transmembrane domains of the HLA-A2 allele of 
the major histocompatibility complex class I molecule. Here 
we report that ligation of the TCK on the cell line expressing 
the yeast phosphatase chimera results in the induction of PTK 
activity, soluble IP generation, and expression of the CD69 
activation antigen. However, the efficiency of TCK signaling 
in the transfectant  expressing the yeast chimera is reduced 
in comparison to signaling demonstrated by our transfectants 
expressing a similar chimeric molecule containing CD45 se- 
quences for its cytoplasmic domain.  Furthermore,  we dem- 
onstrate that a phosphatase-inactive version of the yeast chi- 
mera is unable to restore TCK signal  transduction.  These 
data  provide  the  first  formal  evidence  that  plasma  mem- 
brane-associated tyrosine phosphatase activity is required for 
TCR-mediated  signaling. 
Materlah and Methods 
Cells and Cell Culture.  The wild-type human T cell leukemic 
line Jurkat, and the CD45-deficient Jurkat derivative, J45.01, have 
been described previously (3), and were maintained in RPMI supple- 
mented with 10% FCS, penidllin (1,000 U/nil), streptomycin (1,000 
U/m1), and glutamine  (20 mM). J45/CH11 (7), J45/YP1.6, and 
J45/YPCA4 are transfectants of J45.01, and were maintained in 
the above  medium supplemented additionally with G418 (2 mg/ml). 
Antibodies and Flow Cytometric Analysis.  The following  anti- 
bodies were used in this study: anti-CD45  mAb, 9.4 (American 
Type Culture Collection [ATCC, R_ockviile,  MD]); anti-CD3 mAb, 
Leu4 (Becton Dickinson & Co., Mountain  View, CA); anti-CD3 
mAb, OKT3 (A_TCC); anti-TCK mAb, C305 ([30], gift of A. Weiss 
Howard Hughes Medical Institute and University of California-San 
Francisco, San Francisco, CA); anti-A2 mAb, CKll-351 (gift of 
C. Lutz,  University of Iowa,  Iowa City, IA); anti-PLC^/1 mAb 
(Upstate Biotechnology, Inc., Lake Placid, NY); anti-~" antisera, 
387 ([31], gift of L. Samdson,  Bethesda, MD); antiphosphotyro- 
sine mAb, 4(310 (gift orB. Drucker, Oregon Health Sciences  Univer- 
sity, Portland,  OK); anti-CD69  FITC conjugated  mAb,  Leu23 
(Becton Dickinson & Co.); negative IgG2b control mAb, MOPC- 
195 (Cappel Laboratories, Malvem, PA); negative IgG control FITC- 
conjugated mAb (Becton Dickinson & Co.); and goat anti-mouse 
FITC-conjugated  secondary mAb (Cappel Laboratories). For flow 
cytometric analysis, cells were stained with the indicated mono- 
clonal antibodies followed by a goat anti-mouse HTC-conjugated 
secondary mAb ffnecessary, and analyzed with either a flow cytom- 
eter (Epics 753; Coulter Electronics Corp., Hialeah,  FL) at the 
University of Iowa Flow Cytometry Facility, or a FACScan  |  (Becton 
Dickinson  & Co.). 
eDNA Constructs.  eDNA encoding the A2/YP chimeric mol- 
ecuh was generated using the polymerase chain reaction (PCR) 
using a pBS vector containing  the yeast phosphatase eDNA (gift 
ofg. Deschenes, University of Iowa, Iowa City, IA) as a template, 
and the following primers: sense (5'GCGAGATCTTATATTAGA- 
CAGCGTGAC-3'), containing a 5' BgilI rite, and antisense, O'-TGT- 
CGATATATTTCAAGGAGATCTGCG-5'), containing  a 3' XbaI 
site. The resulting product (from tyrosine seven through the stop 
codon of the yeast phosphatase) was digested with BglII and XbaI, 
gel purified, and ligated into the pGEM A2/CD45 vector (7) pre- 
viously gel purified after digestion with the same restriction  en- 
zymes to remove CD45 sequences. The resulting phsmid was desig- 
nated pGEM A2/YP. The fidelity of the PCR was verified by 
automated DNA sequencing by the DNA core fadh'ty at the Univer- 
sity of Iowa. eDNA encoding the A2/YP chimera was then sub- 
cloned into the pAW Neo3 expression vector. To construct  the 
eDNA encoding the A2/YPCA phosphatase-inactive chimeric mol- 
ecule, the plasmid pRS-YPICA containing  the yeast phosphatase 
eDNA bearing  the cysteine to alanine point  mutation  (gift  of 
R. Deschenes) was digested with the restriction enzymes MluI and 
NsiI,  and the appropriate fragment was gel purified and ligated 
into the phsmid pGEM A2/YP (above), which previously had been 
gel purified after digestion  with the same restriction  enzymes. 
Verification that the resulting phsmid contained the point muta- 
tion was provided by automated  DNA sequencing of the appro- 
priate region by the DNA core facility at the University of Iowa. 
eDNA encoding the A2/YPCA chimera was then subcloned into 
the pAW Neo3 expression vector. 
Transfections  and FACS  ~  Transfections were performed by elec- 
troporation with a Gene Pulser (Bio-Rad Laboratories, Richmond, 
CA) set at 360 mV and 960/xF.  Drug-resistant  cells transfected 
with the A2/YP chimeric molecule were sorted with an Epics 753 
flow cytometer (Coulter  Electronics Corp.) three times with the 
mAb CKll-351 for high expression of the A2 epitope, and once 
with the anti-CD3 mAb OKT3, resulting in establishment of the 
J45/Ypl.6  ceil line. Drug  resistant  ceils transfected  with  the 
A2/YPCA chimeric molecule were sorted four times with the mAb 
CKll-351 to establish the J45/YPCA4 cell line. 
Northern Analysis and Metabolic Labeling.  Total  RNA was iso- 
lated from Jurkat, J45.01, J45/CHll,  and J45/YPl.6 with Tri- 
Reagent  (Molecular Research Center, Cincinnati,  OH). PolyA  § 
IkNA (1.5 #g) extracted with the PolyATract system (Promega 
Corp.,  Madison, WI) was then subjected to electrophoresis in a 
formaldehyde-agarose gel and transferred to a Hybond N blotting 
membrane (Amersham Corp., Arlington  Heights,  IL). The yeast 
phosphatase probe was prepared by random  priming  (Pharmacia 
LKB, Piscataway, NJ) the EcoRI fragment of the A2/YP eDNA. 
Hybridization  was performed at 65~  for 12 h, and the blot was 
washed with SSC solutions increasing in stringency to 2 x. Meta- 
bolic  hbeling  with  [3SS]methionine (160 #Ci/50  x  10  + ceils 
[Amersham Corp.]) was performed for 6 h in methionine-free RPMI 
supplemented with dialyzed 10% FCS, penicillin (1,000 U/ml), 
streptomycin (1,000 U/ml), and glutamine  (20 mM). 
Immunoprecipitations.  Cells  were left unstimulated or were stimu- 
lated for the indicated times with C305 ascites at a final concentra- 
tion of 1:2,500. Cell lysates prepared in either NP-40 (150 mM 
NaC1, 1% NP-40, 10 mM Tris, pH 7.4) or RIPA (150 mM NaC1, 
1% Triton X-100, 0.5% deoxycholate, 50 mM Tris, pH 7.5) lysis 
buffers including protease (50/~g/ml aprotinin, 10/~g/ml leupeptin, 
50 ~g/ml pepstatin A,  1 mM PMSF) and phosphatase (400 nM 
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phosphate) inhibitors were then subjected to immunoprecipitation 
with the indicated antibodies conjugated to protein A (Sigma Chem- 
ical Co., St. Louis, MO) for 2 h at 4~  Immunoprecipitates  were 
washed four times in high-salt  (500 mM NaCI) lysis buffer, sub- 
jected to SDS-PAGE either for autoradiography, or for transfer to 
nitrocellulose for immunoblotting with the indicated antibodies 
followed by an alkaline phosphatase conjugated secondary antibody 
(Bio-Rad Laboratories). Immunoreactive proteins were detected by 
developing with 5-bromo-4-chloro-3-indolyl-phosphate/nitro  blue 
tetrazolium  (BCIP/NBT) as recommended  by the supplier. 
Measurement of  Soluble Inositol  Phosphate  Generation.  Cells were 
loaded with [3H]myoinositol (Amersham  Corp.),  cultured  over- 
night,  and then stimulated with media alone or with media plus 
C305 ascites at a final concentration of 1:2,500. The cells were then 
lysed at the indicated times in a 1:1 mixture of chloroform/meth- 
anol, and soluble IP were isolated by anion-eschange chromatog- 
raphy as described (32). 
GST Fusion Protein Production and Tyrosine Phospkatase Assa2/s. 
cDNAs encoding  the yeast phosphatase portions  of the A2/YP 
and A2/YPCA chimeras were subcloned into the bacterial expres- 
sion vector pGEX-2T (Phannada LKB). GST/YP and GST/YPCA 
fusion proteins  were induced and isolated as described 03), and 
aliquots containing  equivalent amounts of protein were incubated 
with 10 mM o-phospho-L-tyrosine  (Sigma Chemical Co.) and liber- 
ated phosphate was measured by colorimetric assay  as described (3). 
Results 
Characterization  of the Cell Line Expressing  the Yeast Phos- 
phatase Chimera.  To define more precisely the requirements 
for tyrosine phosphatase activity in TCK-mediated signal trans- 
duction, we transfected the CD45-deficient cell line, J45.01, 
with a cDNA encoding a chimeric molecttle consisting of 
a single domain cytosolic tyrosine phosphatase from yeast (29) 
in frame with the transmembrane and extracellular domains 
of the A2 major histocompatibility class I molecule (Fig.  1 
A).  This chimeric molecule, termed A2/YP,  thus contains 
extracellular and transmembrane sequences serving to target 
the cytosolic yeast phosphatase to the plasma membrane. After 
transfection, drug-resistant cells were sorted by flow cytom- 
etry for high  level  expression  of the  A2  epitope,  and  the 
J45/YP1.6  ceU line was established  (Fig.  1 B).  Flow cyto- 
metric analysis  revealed that J45/YP1.6 expressed a similar 
low level of CD45 compared with J45.01, and a similar level 
of TCK when compared with J45/CH11, a previously reported 
transfectant  ofJ45.01 that expresses an A2/CD45  chimeric 
molecule (Hg. 1 B). Northern analysis with a probe specific 
for the yeast phosphatase demonstrated  hybridization  only 
with RNA obtained from J45/YP1.6 (Fig.  1 C); and anti-A2 
immunopredpitates  from [3SS]methionine-labeled  J45/YP1.6 
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Figure  1.  (,4)  Schematic  representation  of  the chimeric  molecules  used 
in th~ study. (B) How cytometric  analysis  of  theJurkat (wild-type),  J45.01 
(CD45-deficient),  J45/YP1.6 (I45.01 tramfect~ with the A2/YP chimera), 
and J45/CHll (145.01 transfected  with the A2/CD45 chimera) cell  lines. 
Cells were  stained  with the negative  control mAb, MOPC 195 (solid  lines), 
anti-CD45 mAb, 9.4 (dotted  lines), anti-A2 mAb, CRll.351 (dashed  lines), 
or anti-TCK mAb, Leu4  (alternating  dotted  and dashed  lines). (C) Northern 
blot analysis  ofRNA isohted  from  Jurkat,  J45.01,  J45/CH11,  andJ45/YP1.6 
with a yeast phosphatase-specific  probe. A parallel blot hybridized  with 
a crossreactive  HLA probe  demonstrated equivalent mRNA loading (not 
shown). (D) Autoradiograph of anti-A2 immunoprecipitates from RIPA 
lysates  of  metabolically  hbded  J45.01,  J45/CH11, and J45/YPl.6 ~  lines. 
Each lane represents 5  ￿  10~ cell equivalents. The predicted molecular 
masses of the A2/CD45 and A2/YP chimeric molecules  are 118 kD and 
75 kD, respectively. cells visualized by SDS-PAGE and autoradiography possessed 
a specific band at 75 kD, the calculated molecular mass of 
the A2/YP chimera (Fig. 1 D). Interestingly, we have found 
that we can only immunoprecipitate the A2/YP chimera from 
lysates of cells sohbilized in harsh detergents, suggesting that 
the A2/YP molecule may associate with insoluble  cellular 
components. 
Expression of the A2/YP Chimeric Molecule Restores Prox- 
imal Signal Transduction.  The earliest detectable biochemical 
event after TCR engagement in wild-type Jurkat is the acti- 
vation of a PTK resulting in the appearance of multiple newly 
tyrosine phosphorylated proteins (Fig. 2 A). In J45.01, this 
event is uncoupled from TCR ligation (Fig. 2 A  and refer- 
ence 3). As reported previously, expression of an A2/CD45 
chimeric molecule (Fig. 1 A) on the J45/CH11 cell line (Fig. 
1 B) rescues this defect (Fig. 2 A  and reference 7). Interest- 
ingly, the A2/YP chimera expressed  on J45/YP1.6 also rescues 
TCR-mediated FTK activation, with nearly an identical pat- 
tern of phosphoprotein induction (Fig.  2 A). 
Two physiologically  rdevant substrates of the TCR-activated 
PTK are the phosphoinositide-specific  enzyme PLC3q (34, 
35) and the ~'chain of the TCR (10, 11). Tyrosine phosphory- 
lation of ~'is thought to be important in TCR-mediated fig- 
naling because it allows ~" to associate with the ZAP-70 FFK 
(15, 17), and the SH2 domain adaptor protein Shc (36). There- 
fore we investigated the tyrosine phosphorylation state of ~" 
in J45/YPl.6 in response to increasing periods of TCR stim- 
ulation, and compared it with responses generated in Jurkat 
andJ45/CHll (Fig. 2 B). As shown, ~'becomes  tyrosine phos- 
phoryhted in J45/YPl.6, but to a lesser  degree and with slower 
kinetics than in either Jurkat or J45/CHll.  Tyrosine phos- 
phorylation of ~" peaks after 5 min of TCK stimulation in 
J45/YPl.6,  compared with 1 rain of TCR stimulation in 
both Jurkat  and J45/CHll.  In  the  same experiment,  an 
antiphosphotyrosine-reactive protein migrating at 70 kD was 
observed in each lane phospho-~"  was detected (not shown). 
This protein had the same kinetics of appearance as phospho-~" 
and was presumed  to be ZAP-70. 
Figure 2.  Expression of the A2/YP chimera 
restores TCR-mediated  phosphoprotein  induc- 
tion. (A) Time course of phosphoprotein induc- 
tion in  J45.01, Jurkat, J45/CHll, and  J45/YP1.6 
after TCR ligation. Cells were left unstimuhted 
or were stimulated for the indicated times with 
antbTCR mAb C305  (ascites, final concentra- 
tion 1:2,500). NP-40 lysates were subjected to 
10% SDS-PAGE, transferred to nitrocellulose, 
and immunoblotted  with the antiphosphotyro- 
sine mAb 4(310. Each lane represents  106 cell 
equivalents. (B) Time course of ~" phosphoryla- 
tion in  J45.01, Jurkat, J45/CHll, and J45/YP1.6 
after TCR ligation. NP-40 cell lysates were sub- 
jected to immunoprecipitation with the anti-~" 
antiserum 387,  subjected to SDS 12% PAGE, 
transferred to nitrocellulose, and immunoblotted 
with 387 (bottom,  10r  cell equivalents/lane)  or 
4G10 (top,  5  x  107 cell equivalents/lane).  (C) 
Time  course  of  PLC'y  1 phosphoryhtion in  J45.01, 
Jurkat, J45/CH11,  andJ45/YPl.6 after TCR li- 
gation. NP-40 cell lysates were subjected to im- 
munoprecipitation  with the anti-PLC3,1 mAb, 
subjected to SDS 8% PAGE, transferred to nitro- 
cellulose, and immunoblotted  with anti-Pl.C',/1 
mAb  (bottom, 107 cell equivalents/lane) or 4G10 
(top,  5  x  107 cell equivalents/lane). 
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positively regulates its enzymatic activity (37); therefore this 
event also is thought to be physiologicaUy relevant in TCR- 
mediated signaling. In a manner analogous to that described 
for ~', we investigated tyrosine phosphorylation of PLC3,1 
in Jurkat, J45.01, J45/CHll,  and J45/YPL6 in response to 
increasing periods of TCR stimulation (Fig. 2 C). As shown, 
PLC3,1 becomes tyrosine phosphorylated in J45/YPl.6 with 
similar kinetics to those observed for ~', peaking after 5 min 
of TCR stimulation, compared with 1 rain for both Jurkat 
and J45/CHll. Additionally, the amount of PLC3,1 that be- 
comes tyrosine phosphorylated varies considerably between 
the cell lines, with the bands representing phosphorylated 
PLC3,1 from Jurkat  being more intense than  those from 
J45/CHll, which in turn are more intense than those from 
J45/YPl.6. Taken together, these results suggest that expres- 
sion of the A2/YP chimera is sufficient for the TCR to couple 
with the PTK signal transduction pathway. 
Activation of PLC3'I by tyrosine phosphorylation should 
lead to the generation of phosphatidylinositol-derived  second 
messengers. We examined further the integrity of TCR sig- 
naling in J45/YP1.6 by measuring production of soluble IP 
in response to increasing periods of TCR stimulation (Fig. 
3). TCK stimulation in J45/YP1.6 generates a threefold in- 
crease in soluble IP after 30 rain, compared to a 6-fold induc- 
tion in J45/CHll,  and a 12-fold response in Jurkat. Addi- 
tionally Jurkat and J45/CHll demonstrate a response within 
5 min, whereas J45/YP1.6 does not respond until 10 min 
of stimulation. This slower pattern of induction in J45/YP1.6 
relative to J45/CH11 and Jurkat may reflect the differences 
in kinetics of PLC3'I tyrosine phosphorylation demonstrated 
among the ceils (Fig. 2 C). Likewise, the differences in total 
soluble IP induction may reflect the amount of PLC'),I that 
became tyrosine phosphorylated in each of the ceils, which 
was greater in Jurkat relative to J45/CHll relative to J45/ 
YP1.6  (Fig.  2 C). 
Expression of the A2/YP Chimeric Molecule Restores Distal 
Signal Transduction.  We next assessed TCK-stimulated ex- 
pression of the CD69 antigen (38, 39) as a more distal marker 
of activation in the four cell lines (Fig. 4). As shown, TCK 
ligation results in increased CD69 expression in Jurkat, but 
not J45.01. BothJ45/CHll andJ45/YPl.6 express increased 
levels of CD69 after TCK ligation, however neither cell ex- 
presses this activation antigen to levels seen on the wild-type 
parent.  Interestingly, J45/YPl.6  and J45/CH11  exhibit a 
similar augmentation of CD69 expression in response to TCK 
ligation, indicating that the differences in proximal signal 
transduction observed between the two cell lines do not re- 
sult in differences in this measure of distal  signaling. 
A Phosphatase Inactive A2/YP Chimeric Molecule Is Unable 
to Support Signal Transduction.  To address whether the tyro- 
sine phosphatase activity of the A2/YP chimera was respon- 
sible for its ability to restore signaling in J45.01,  we con- 
structed a  phosphatase-deflcient version of the  molecule. 
Tyrosine phosphatases possess an active site cysteine residue 
which is essential for enzymatic activity (40). Thus we gener- 
ated an A2/YP molecule with the essential cysteine residue 
mutated to an alanine.  To demonstrate that this molecule 
(A2/YPCA) possessed no enzymatic activity, we subcloned 
eDNA encoding the yeast phosphatase portion of the chi- 
mera into the prokaryotic expression vector pGEX-2T, and 
subjected  bacterial-expressed  fusion protein to an in vitro 
phosphatase assay. As shown, the cysteine to alanine muta- 
tion completdy abrogates the enzymatic activity of the yeast 
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Figure  3.  TCR-mediated  soluble  IP  production  in Jurkat,  J45.01, 
J45/CH11,  and J45/YP!.6. Soluble I1) production was measured after stim- 
ulation of the four cell lines with medium alone (time -  0), or with anti- 
TCR mAb (C305  ascites, final concentration 1:2,500) for the indicated 
periods of time. 
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Figure 4.  TCR-mediated CD69 expttssion inJurkat, J45.01, J45/CHll, 
and J45/YP1.6.  C.lls were incubated overnight with media alone, or media 
plus C305 (asdtes, final concentration 1:2,500), stained with control IgG 
or anti-CD69 mAb Leu23, and analyzed by flow cytometry. Light solid 
lines, control IgG (C305-stimuhted cells); dashed lines, anti-CD69 (un- 
stimulated cells); heavy solid lines, anti-CD69 (C305-stimulated cells). 
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Figure 5.  (/1) Flow cytometric analysis of J45/YPCA4 045.01 trans- 
fected with the A2/YPCA chimera). Cells were stained with the negative 
control mAb, MOPC 195 (solid lines), anti-CD45 mAb, 9.4 (dashed lines), 
anti-A2 mAb CRll.351 (alternating dotted and dashed lines), or anti-TCR 
mAb Leu4 (dotted lines). (B) The cysteine to alanine mutation completely 
abolishes the enzymatic activity of the yeast phosphatase.  Bacterial ex- 
pressed GST/YP (yeast phosphatase)  and GST/YPCA (yeast phosphatase 
containing the cysteine to alanine mutation) were subjected to an in vitro 
tyrosine phosphatase assay. (C) TCR ligation of J45/YPCA4 does not 
result in production of soluble IP. Soluble IP were measured in J45.01, 
J45/YPCA4, andJ45/YPL6 after stimulation with medium alone (time = 
0), or with anti-TCR mAb (C305 ascites, final concentration 1:2,500) for 
the indicated periods of time. 
phosphatase (Fig.  5 A).  We  transfected  J45.01  with  the 
A2/YPCA construct and established  the J45/YPCA4 cell 
line (Fig.  5 B).  Ligation of the TCR on these cells does 
not result in the activation of a PTK (not shown), nor does 
it result in the production of soluble IP (Fig.  5 C). These 
data provide the first  formal evidence  that plasma mere- 
brane-associated tyrosine phosphatase activity is required for 
the TCR to couple to its signaling machinery. 
Discuuion 
Much has been learned in recent years regarding the role 
of CD45 in TCR-mediated signal transduction. Evidence 
generated through the study of CD45-deficient T cell lines 
has demonstrated the essential role that this molecule plays 
in the regulation of signals initiated by ligation of the TCR. 
One proposed model for the function of CD45 in TCR- 
mediated signal transduction is that CD45  is required to 
dephosphorylate one or more src family trI'K on their nega- 
tive regulatory COOH-terminal tyrosine residues, allowing 
their function in the propagation of the TCR-initiated signal. 
The experiments in this report describe J45/YP1.6, a cell 
line derived from  J45.01, a CD45-ddicient variant of theJurkat 
human T cell leukemic line. J45/YP1.6 is a stable line trans- 
fected with cDNA encoding a chimeric protein consisting 
of the extracellular  and transmembrane domains of the A2 
allele of the MHC class I molecule in frame with a single 
domain nonreceptor tyrosine phosphatase from yeast (A2/YP). 
Expression of the A2/YP chimera partially rescues the TCR 
signaling defect exhibited by J45.01. Stimulation of the TCR 
on J45/Yp1.6 results in the induction of PTK activity with 
resultant tyrosine phosphorylation of numerous cellular pro- 
teins including the ~" chain of the TCR and PLC'),I. As ex- 
pected, these events result in the production of soluble ino- 
sitol  phosphates, leading eventually to more distal  events 
associated with T  cell activation such as the expression of 
the CD69 activation antigen. The signaling phenotype of 
J45/YP1.6 is in marked contrast to that ofJ45.01 which ex- 
hibits no response to TCR engagement. These data thus dem- 
onstrate that a molecule which has the appropriate enzymatic 
activity, but little other homology to CD45, can function 
to support TCR signaling. 
Additionally, experiments in this report provide the first 
formal demonstration of the requirement for surface tyro- 
sine phosphatase activity for effective TCR signal transduc- 
tion. Data supporting this conclusion results  from experi- 
ments using a second transfectant, J45/YPCA4. This cell line, 
also derived from J45.01,  expresses a protein identical to the 
A2/YP chimera except for a single amino acid change that 
abolishes enzymatic activity. Although  J45/YPCA4 expresses 
similar amounts of chimeric molecule as does J45/YP1.6, TCR 
stimulation fails to result in the appearance of second mes- 
sengers. 
Throughout the course of these experiments we noted 
differences in signaling ability, both between our transfec- 
tants when compared with each other, and between our trans- 
fectants when compared with wild-type  Jurkat. The e6iciency 
of TCR-mediated signal transduction in J45/YP1.6 is con- 
siderably  reduced in  comparison to  both Jurkat,  and  to 
J45/CHll, a previously described transfectant ofJ45.01 which 
expresses an A2/CD45 chimeric molecule. Although J45/ 
YP1.6 and J45/CHll both demonstrate decreased signaling 
e~ciency in comparison with Jurkat, the defect exhibited by 
1364  Rescue  of CD45 Deficiency with a Yeast Tyrosine Phosphatase J45/YP1.6 is considerably greater than that demonstrated by 
J45/CH11, even though both transfectants express similar levels 
of A2 chimeric protein and TCR. One potential explanation 
for why both the A2/YP and A2/CD45 chimeras fail to re- 
store TCR signaling to wild-type levels is that the extracel- 
lular and/or transmembrane domains of CD45 mediated pro- 
tein-protein  interactions  with  other  molecules that  may 
potentiate the TCR signaling response. Likewise, one pos- 
sible explanation for the observed discrepancy of signaling 
in J45/CHll relative to J45/YPI.6 is that the yeast phospha- 
tase lacks CD45 cytoplasmic sequences that optimize addi- 
tional protein-protein interactions, possibly including those 
that direct interactions with physiological substrates. 
An additional potential explanation for the discrepancy in 
signaling observed between J45/YP1.6 and J45/CH11 is that 
the A2/YP molecule possesses only one enzymatically active 
tyrosine phosphatase domain, while CD45 and the A2/CD45 
chimeric molecule each contained two tandem tyrosine phos- 
phatase catalytic domains. Although the relative contribu- 
tion of each domain to the overall activity of CD45 remains 
controversial, evidence suggests that both domains may play 
important roles. However, preliminary evidence from our lab- 
oratory in~cates that transfection ofJ45.01 with an A2/CD45 
chimera bearing a cysteine to ahnine substitution in the second 
phosphatase domain also rescues TCIk signal transduction 
(data not shown). Currently we are performing quantitative 
signaling assays to determine if there are consistent differ- 
ences in signaling ability of our cells containing various CD45 
cytoplasmic domain mutations.  Additionally, we are con- 
structing a cDNA which encodes extracellular and transmem- 
brahe domains from A2 in flame with two tandem yeast phos- 
phatase domains with a spacer of similar length to the CD45 
interphosphatase region. Transfection of these cDNAs into 
CD45-deficient cell lines followed by evaluation of TCR func- 
tion should help to clarify further the structural requirements 
for tyrosine phosphatases  involved in  the TCR  signaling 
pathway. 
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